$651 Million is the total value of Bill & Melinda Gates Foundation's 8 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ZY | New | ZYMERGEN INC | $2,000,000 | – | 59,970 | +100.0% | 0.31% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-11-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CUREVAC N V | 15 | Q2 2024 | 58.0% |
VIR BIOTECHNOLOGY INC | 15 | Q2 2024 | 32.0% |
BIONTECH SE | 15 | Q2 2024 | 35.8% |
IMMUNOCORE HLDGS PLC | 14 | Q2 2024 | 44.6% |
BUTTERFLY NETWORK INC | 14 | Q2 2024 | 3.8% |
ATRECA INC | 14 | Q1 2024 | 5.3% |
AMYRIS INC | 12 | Q3 2023 | 1.2% |
EXSCIENTIA | 11 | Q2 2024 | 13.6% |
LUMIRADX LTD | 10 | Q1 2024 | 18.0% |
ZYMERGEN INC | 6 | Q3 2022 | 0.3% |
View Bill & Melinda Gates Foundation's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
LumiraDx Ltd | August 03, 2022 | 19,859,773 | 15.8% |
Atreca, Inc. | February 16, 2021 | 1,396,644 | 4.7% |
Liquidia Technologies Inc | February 12, 2020 | 119,678 | 0.5% |
X4 Pharmaceuticals, Inc | March 15, 2019 | 120,363 | 1.8% |
Arsanis, Inc. | February 13, 2018 | 722,179 | 5.1% |
View Bill & Melinda Gates Foundation's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-09-03 |
13F-HR | 2024-08-14 |
13F-HR | 2024-05-14 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-12 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-12 |
View Bill & Melinda Gates Foundation's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.